Clinical Trial Update: Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. [Phase 4]

View source ↗

Summary

This is a Phase 4 clinical trial update evaluating aflibercept (EYLEA) as secondary or third-line treatment for neovascular age-related macular degeneration, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: UNKNOWN